Claus Wittekindt

Claus Wittekindt

Auto-generated profile, based on publicly available information

Claus Wittekindt

Klinikum Dortmund gGmbH

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2017 in Frontiers in Oncology
Verified
Journal Article
Open access
NWNora Würdemann
Nora Würdemann
SWSteffen Wagner
Steffen Wagner
SSShachi Jenny Sharma
Shachi Jenny Sharma
EPElena-Sophie Prigge
Elena-Sophie Prigge
MRMiriam Reuschenbach
Miriam Reuschenbach
CWClaus Wittekindt
Claus Wittekindt
Introduction: The purpose of this study was to test whether the 8th edition of the AJCC/UICC TNM staging system (UICC) precisely differentiates between stages and reflects disease outcome in Human Papilloma Virus (HPV)-associated Oropharyngeal squamous cell carcinoma (OPSCC). Patients and methods: OPSCC patients that were diagnosed between 2000 and 2016 were included in this analysis and HPV-status was determined by combined DNA- and p16-testing. Stratification was done according to 7th and 8th UICC staging rules. Incidence trends of HPV-associated tumorigenesis, 5-year overall survival (OS) according to tumor stages as well as the influence of therapy and risk factors towards the outcome were calculated using Kaplan–Meier method and Cox proportional-hazards model. Results: A significant increase (2000; n=8/39 (21%)- 2015; n=17/32 (53%); p=0.002) in HPV-associated OPSCC was seen in the observation period. Together, 150/599 (25.0%) of the patients had HPV driven OPSCC and 64.7% of curative treatments in all OPSCC patients included upfront surgery of the primary and the neck. 7th edition staging rules led to no discrimination in all respective four UICC stages in HPV OPSCC underlining the need for new staging rules. However, only discrimination between stages I vs. II and III vs. IV was significant in our patients with HPV-OPSCC (94.4% vs. 77.5%; p=0.031 and 63.9% vs, 25.0%; p=0.013), and stages II vs. III did not differ in OS rates (p=0.257), when applying the new staging rules. For HPV negative OPSCC significant outcome differences were only seen between UICC stages III vs. IV (57.6% vs. 35.2%; p=0.012). Discussion: While the 7th edition of UICC shows invalid discrimination between stages, 8th edition is more suitable for HPV-associated carcinoma. Due to lack of differentiation between stages II and III further adaption is essential.

4 May 2017 in British Journal of Cancer
Verified
Journal Article
Open access
SWSteffen Wagner
Steffen Wagner
CWClaus Wittekindt
Claus Wittekindt
SSShachi Jenny Sharma
Shachi Jenny Sharma
NWNora Wuerdemann
Nora Wuerdemann
TJTheresa Jüttner
Theresa Jüttner
JKJens Peter Klussmann
Jens Peter Klussmann
Upfront surgery is a valuable treatment option for oropharyngeal squamous cell carcinoma (OPSCC) and risk stratification is emerging for treatment de-escalation in human papillomavirus (HPV)-related OPSCC. Available prognostic models are either based on selected, mainly non-surgically treated cohorts. Therefore, we investigated unselected OPSCC treated with predominantly upfront surgery. All patients diagnosed with OPSCC and treated with curative intent between 2000 and 2009 (n=359) were included. HPV association was determined by HPV-DNA detection and p16INK4a immunohistochemistry. Predictors with significant impact on overall survival (OS) in univariate analysis were included in recursive partitioning analysis. Risk models generated from non-surgically treated patients showed low discrimination in our cohort. A new model developed for unselected patients predominantly treated with upfront surgery separates low-, intermediate- and high-risk patients with significant differences in 5-year OS (86%, 53% and 19%, P<0.001, respectively). HPV status is the most important parameter followed by T-stage in HPV-related and performance status in HPV-negative OPSCC. HPV status and ECOG remained important parameters in risk models for patients treated with or without surgery. Regardless of treatment strategies, HPV status is the strongest predictor of survival in unselected OPSCC patients. The proposed risk models are suitable to discriminate risk groups in unselected OPSCC patients treated with upfront surgery, which has substantial impact for design and interpretation of de-escalation trials.

6 July 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
SWSteffen Wagner
Steffen Wagner
EPElena-Sophie Prigge
Elena-Sophie Prigge
NWNora Würdemann
Nora Würdemann
HRHenrike Reder
Henrike Reder
ABAyman Bushnak
Ayman Bushnak
Jens Peter KlussmannJens Peter Klussmann
Jens Peter Klussmann
Background: A remarkably better prognosis is associated with oropharyngeal squamous cell carcinomas (OPSCC) driven by human papillomaviruses (HPV) compared with HPV-negative OPSCC. Consequently, de-escalation of standard treatment has been suggested. Due to modest specificity rates, debates are ongoing, whether p16INK4a, a surrogate marker for HPV-driven OPSCC, is sufficient to correctly identify those tumours and avoid substantial HPV misattribution and thus undertreatment of patients by de-escalation. Robust data estimating the proportion of potentially undertreated patients are missing. Methods: We assessed a large-scale cohort of consecutively included OPSCC diagnosed between 2000 and 2017 for HPV–DNA, HPV genotypes, p16INK4a expression and multiple tumour- and patient-related risk factors, and investigated their impact on patients’ survival in comprehensive uni- and multivariate analyses. Results: Aetiological relevance of HPV (p16INK4a- and high-risk HPV–DNA-positivity) was detected in 27.1% (n = 192) of OPSCC, with HPV16 being the most abundant HPV type (94.6%). In 5.5% patients (n = 39), p16INK4a overexpression but no HPV–DNA was detected. Principal component and survival analyses revealed that 60.6% of these p16INK4a-positive OPSCC lacking HPV–DNA did not resemble HPV16-driven but HPV-negative OPSCC regarding risk-factor profile and overall survival. Notably, this group represented 10.6% of all p16INK4a-overexpressing OPSCC. Conclusions: p16INK4a as a single marker appears insufficient to indicate OPSCC patients suitable for treatment de-escalation.

22 March 2018 in Laryngo-Rhino-Otologie
Verified
Journal Article
Open access
PDF file
CWClaus Wittekindt
Claus Wittekindt
SWSteffen Wagner
Steffen Wagner
SSShachi Jenny Sharma
Shachi Jenny Sharma
NWNora Würdemann
Nora Würdemann
JKJennifer Knuth
Jennifer Knuth
JKJens Peter Klußmann
Jens Peter Klußmann
Zusammenfassung: Kopf-Hals-Tumore sind die sechst-häufigste Krebsart mit über 500000 jährlich gemeldeten Fällen weltweit. Die Hauptrisikofaktoren sind Tabak- und Alkoholkonsum, wobei v. a. Oropharynxkarzinome (OSCC) vermehrt eine Assoziation mit humanen Papillomaviren (HPV) aufweisen. Bei HPV-assoziierten und HPV-negativen OSCC handelt es sich bezüglich biologischer Charakteristika, Therapieansprechen und Prognose der Patienten um 2 eigenständige Entitäten, die allerdings bisher identisch behandelt werden. Bei HPV OSCC spielen neben der Aktivität viraler Onkoproteine auch genetische (Mutationen und chromosomale Aberrationen) und epigenetische Veränderungen eine entscheidende Rolle bei der Krebsentstehung. Aufgrund des besseren Therapieansprechens wird aktuell über die Einführung einer De-Intensivierung der Therapie und über zielgerichtete Therapieoptionen für Patienten mit HPV OSCC diskutiert. Ein vielversprechendes zielgerichtetes Therapiekonzept ist bspw. die Immuntherapie. Besonders intensiv wird derzeit die Anwendung von Checkpoint-Inhibitoren (z. B. gegen PD1) erforscht. Mithilfe sogenannter Flüssigbiopsien sollen zukünftig weitere Biomarker, in Form von viraler DNA oder Tumor-Mutationen, zur Überwachung des Krankheitsverlaufs und frühzeitigen Erkennens von Therapieversagen eingesetzt werden. Zur primären Prophylaxe einer Tumorentstehung ist die HPV-Impfung von männlichen und weiblichen Jugendlichen empfehlenswert.

24 May 2018 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
CGChristian Grønhøj
Christian Grønhøj
DJDavid H. Jensen
David H. Jensen
CDChristian Dehlendorff
Christian Dehlendorff
LMLinda Marklund
Linda Marklund
SWSteffen Wagner
Steffen Wagner
Christian von BuchwaldChristian von Buchwald
Christian von Buchwald
The proxy marker for human papillomavirus (HPV), p16, is included in the new AJCC 8th/UICC 8th staging system, but due to incongruence between p16 status and HPV infection, single biomarker evaluation could lead to misallocation of patients. We established nomograms for overall survival (OS) and progression-free survival (PFS) in patients with oropharyngeal squamous cell carcinoma (OPSCC) and known HPV-DNA and p16 status, and validated the models in cohorts from high- and low-prevalent HPV countries. Consecutive OPSCC patients treated in Denmark, 2000–2014 formed the development cohort. The validation cohorts were from Sweden, Germany, and the United Kingdom. We developed nomograms by applying a backward-selection procedure for selection of variables, and assessed model performance. In the development cohort, 1313 patients, and in the validation cohorts, 344 German, 503 Swedish and 463 British patients were included. For the OS nomogram, age, gender, combined HPV-DNA and p16 status, smoking, T-, N-, and M-status and UICC-8 staging were selected, and for the PFS nomogram the same variables except UICC-8 staging. The nomograms performed well in discrimination and calibration. Our nomograms are reliable prognostic methods in patients with OPSCC. Combining HPV DNA and p16 is essential for correct prognostication. The nomograms are available at www.orograms.org.

11 May 2017 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
JIJ. Inhestern
J. Inhestern
HSH. Schmalenberg
H. Schmalenberg
ADA. Dietz
A. Dietz
NRN. Rotter
N. Rotter
GMG. Maschmeyer
G. Maschmeyer
Orlando Guntinas-LichiusOrlando Guntinas-Lichius
Orlando Guntinas-Lichius
Induction chemotherapy (ICT) with docetaxel, cisplatin and fluorouracil (TPF) followed by radiotherapy is an effective treatment option for locally advanced head and neck cancer. This phase II study investigated the effectivity of a split-dose TPF ICT before surgery for locally advanced resectable (stage III/IVA) oral and oropharyngeal cancer. Patients received TPF split on two dosages on days 1 and 8 per cycle (30 mg/m2 docetaxel, 40 mg/m2 cisplatin, 2000 mg/m2 fluorouracil per week). Responders (reduction tumor volume ≥30% after first cycle) received three 3-week cycles and non-responders only one cycle before surgery and postoperative radio(chemo)therapy (RCT). The primary endpoint was progression-free survival rate after 24 months. Secondary endpoints were amongst others overall survival, histopathological response to ICT, toxicity, quality of life and swallowing function. Fifty-four patients (91% stage IVA, 87% male, 72% oropharyngeal cancer, 70% responders) were eligible for a per-protocol analysis. The progression-free survival rate after 24 months was 88.5% for responders and 60.6% for non-responders (P = 0.005). The overall survival rate after 24 months was 97.3% for responders and 73.7% for non-responders (P = 0.032). The rate of histopathological complete remission of the primary tumor was higher in responders (P = 0.015). High-risk classification for postoperative RCT was lower in responders (P < 0.0001). The most common grade 3+ adverse event was neutropenia in 26% of patients during ICT and mucositis in 13% during postoperative RCT. During treatment and follow-up quality of life and swallowing function was not different between responders and non-responders. Patients with oral and oropharyngeal cancer responding to split-dose TPF before surgery and postoperative RCT show good oncological results. The tri-modal treatment regime was well tolerated. ICT using tumor response as criterion for duration of ICT before surgery of oral and oropharyngeal cancer merits additional investigation in a phase III study. NCT01108042.